Gold is 2025’s best performer. UBS sees more upside
In a challenging market environment, Modular Medical (TASE:BLWV) (MODD) stock has touched a 52-week low, reaching a price level of $0.82. With a market capitalization of $34.4 million, the company maintains a strong liquidity position, evidenced by a healthy current ratio of 5.3. InvestingPro analysis suggests the stock is currently oversold. This downturn reflects a significant retreat from better-performing times, with the company’s shares experiencing a steep 1-year change, plummeting by -55.27%. Investors are closely monitoring the stock as it navigates through the current economic headwinds, which have been particularly unforgiving to the healthcare technology sector. The stock’s notable -3.72 beta indicates strong counter-market movements, while maintaining more cash than debt on its balance sheet. The 52-week low serves as a critical indicator for both the company’s recent performance and investor sentiment, as market participants weigh the potential for a rebound against ongoing industry and broader market pressures. For deeper insights and 10+ additional exclusive tips on MODD, visit InvestingPro.
In other recent news, Modular Medical, Inc. has announced a partnership with Nudge BG to develop an advanced Automated Insulin Delivery (AID) system. This collaboration aims to create a full closed-loop system that simplifies diabetes management by eliminating the need for mealtime insulin announcements. The new system will integrate Nudge BG’s adaptive technology with Modular Medical’s MODD1 insulin pump, which is designed to be user-friendly and cost-effective. The combined technology is expected to adjust insulin delivery based on continuous glucose monitoring data, reducing the burden on individuals with insulin-requiring diabetes. Lane Desborough, CEO of Nudge BG, highlighted the goal of automating mealtime insulin delivery to help users achieve glycemic goals with less effort. Paul DiPerna, President and CTO of Modular Medical, stated that this partnership aligns with their mission to make diabetes management more accessible and less complex. The press release notes that while the project has potential, there are risks and uncertainties involved, and the statements should not be viewed as guarantees of future performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.